ESPE2022 Poster Category 2 Diabetes and Insulin (43 abstracts)
Effect of combined hormonal contraceptives use in telomere length and metabolic profile in young women with T1D
Franco Giraudo 1,2,3 , Cecilia Lardone 1 , Andrea Castro 1 , Patricia López 1,4 , Germán Iñiguez 1 , Paulina Merino 1,5 , Abril Salinas 1,6 , Fernando Cassorla 1 & Ethel Codner 1
1Institute of Maternal and Child Research (IDIMI), School of Medicine University of Chile, Santiago, Chile; 2San Borja Arriarán Clinical Hospital, Pediatric Endocrinology Unit, Santiago, Chile; 3Juvenile Diabetes Foundation of Chile (FDJ), Santiago, Chile; 4San Borja Arriarán Clinical Hospital, Cytogenetics Unit, Santiago, Chile; 5San Borja Arriarán Clinical Hospital, Pediatric Gynecology Unit, Santiago, Chile; 6Chilean Institute of Reproductive Medicine (ICMER), Santiago, Chile
Introduction: The metabolic effects of oral hormonal contraception (OC) on telomere length (RTL) in young women with T1D are unknown.
Objective: To determine the effect of using an OC on glycemic control, inflammatory profile, and RTL in young women with T1D and healthy women without diabetes (C).
Methodology: T1D (n:20, age: 20.6 ± 3.3 years) and C (n:22, age 20.2 ± 3 years) used OC (150 mg desogestrel and 30 mg ethinyl estradiol) for 18 months. HbA1c, C-reactive protein measured by an ultrasensitive assay (usCRP), and RTL were evaluated at baseline, 12, and 18 months. RTL was determined using the MMq-PCR technique. DNA was obtained from blood mononuclear cells. Non-parametric statistics and linear regression were used.
Results: RTL was similar in the T1D and C groups at baseline, 12, and 18 months. In C, the RTL decreased by 0.2 ± 0.4 at 18 months (P=0.044). The decrease in RLT in the T1D group did not reach statistical significance (P=0.096). In the T1D group, increasing BMI (Spearman's coefficient of -0.446; P=0.049) and increasing usCPR (Spearman's coefficient of -0.541; P=0.037) correlated with decreasing RTL. Changes in HbA1c did not correlate with changes in RTL (P>0.05).
| T1D | Controls | |||||
| Basal (n:20) |
12 months (n:20) |
18 months (n:15) |
Basal (n:21) |
12 months (n:21) |
18 months (n:18) |
|
| HbA1c, % HbA1c, nmol/mol |
7.9 (6.9 – 8.6) 63 (52 – 70) |
8 (6.9 – 8.4) 64 (52 – 68) |
7.5 (6.8 – 8.3) 58 (51 – 67) |
|||
usCRP, ng/ml |
2.73# (1.04 – 4.35) |
5.86#* (2.55 – 13.87) |
8.16* (2.42 – 12.13) |
1 (0.33 – 2.39) |
3.1* (1.19 – 5.56) |
7.5* (5.01 – 12.4) |
| RTL | 1.61 ± 0.49 | 1.39 ± 0.41 | 1.35 ± 0.41 | 1.54 ± 0.33 | 1.49 ± 0.43 | 1.43 ± 0.28* |
| Data are shown as median (interquartile range) or mean ± standard deviation. # P<0.05 between T1D and C. *P<0.05 compared to baseline. | ||||||
Conclusions: The use of OC for eighteen months did not deteriorate glycemic control in young women with T1D. However, subclinical inflammation was observed in both groups. These results suggest that despite the lack of an adverse effect of the OC on glycemic control in women with T1D, attention should be given to other pro-inflammatory risk factors such as higher BMI and usCRP, which are associated with decreasing telomere length in young women.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more